These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 19391309)

  • 1. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in CML.
    Larson RA
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):S3-5. PubMed ID: 19391309
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic monitoring of drug plasma concentrations and improved clinical outcomes in GIST.
    Demetri GD
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):S6-7. PubMed ID: 19391310
    [No Abstract]   [Full Text] [Related]  

  • 3. Correlation between trough imatinib plasma concentration and clinical response in chronic myeloid leukemia.
    Mahon FX; Molimard M
    Leuk Res; 2009 Aug; 33(8):1147-8; author reply 1149-50. PubMed ID: 19395027
    [No Abstract]   [Full Text] [Related]  

  • 4. Pharmacologic monitoring and determinants of intracytoplasmic drug levels.
    Mahon FX
    Best Pract Res Clin Haematol; 2009 Sep; 22(3):381-6. PubMed ID: 19959088
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Longstanding remission of adult onset Still's disease under imatinib therapy in a patient with chronic myelogenous leukemia.
    Nagasaki Y; Miyamoto T; Henzan H; Nagafuji K; Harada M; Akashi K
    J Rheumatol; 2009 Jun; 36(6):1349-51. PubMed ID: 19509096
    [No Abstract]   [Full Text] [Related]  

  • 6. Tumor lysis syndrome after starting treatment with Gleevec in a patient with chronic myelogenous leukemia.
    Al-Kali A; Farooq S; Tfayli A
    J Clin Pharm Ther; 2009 Oct; 34(5):607-10. PubMed ID: 19744017
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resolution of rheumatoid arthritis symptoms with imatinib mesylate.
    Vernon MR; Pearson L; Atallah E
    J Clin Rheumatol; 2009 Aug; 15(5):267. PubMed ID: 19654496
    [No Abstract]   [Full Text] [Related]  

  • 8. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
    Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
    Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dasatinib: for some difficult cases of adult leukaemia.
    Prescrire Int; 2008 Aug; 17(96):149-50. PubMed ID: 19496239
    [No Abstract]   [Full Text] [Related]  

  • 10. Nilotinib shows prolonged intracellular accumulation upon pulse-exposure: a novel mechanism for induction of apoptosis in CML cells.
    Wagner MC; Dziadosz M; Melo JV; Heidel F; Fischer T; Lipka DB
    Leukemia; 2013 Jul; 27(7):1567-70. PubMed ID: 23232286
    [No Abstract]   [Full Text] [Related]  

  • 11. Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia.
    Foroni L; Gerrard G; Nna E; Khorashad JS; Stevens D; Swale B; Milojkovic D; Reid A; Goldman J; Marin D
    Am J Hematol; 2009 Aug; 84(8):517-22. PubMed ID: 19544476
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
    Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
    Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
    [No Abstract]   [Full Text] [Related]  

  • 13. Promises and pitfalls of oral cancer chemotherapy.
    Ergolin MJ
    Clin Adv Hematol Oncol; 2009 Feb; 7(2):S8-10. PubMed ID: 19391311
    [No Abstract]   [Full Text] [Related]  

  • 14. [Correlation of quantification of major bcr-abl mRNA between TMA (transcription mediated amplification) method and real-time quantitative PCR].
    Yagasaki F; Niwa T; Abe A; Ishikawa M; Kato C; Ogura K; Sasaki H; Kyo T; Jinnai I; Bessyo M; Miyamura K
    Rinsho Ketsueki; 2009 Jun; 50(6):481-7. PubMed ID: 19571508
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring treatment results in patients with chronic myelogenous leukemia.
    Radich JP
    Clin Adv Hematol Oncol; 2008 Aug; 6(8):577-8, 586. PubMed ID: 18820599
    [No Abstract]   [Full Text] [Related]  

  • 16. Molecular monitoring during dose reduction predicts recurrence after TKI cessation in CML.
    Gottschalk A; Glauche I; Cicconi S; Clark RE; Roeder I
    Blood; 2020 Mar; 135(10):766-769. PubMed ID: 31935278
    [No Abstract]   [Full Text] [Related]  

  • 17. Reduction of BCR-ABL1 mutant clones after discontinuation of TKI therapy.
    Beel K; Janssens A; Verhoef G; Vandenberghe P
    Leuk Res; 2009 Dec; 33(12):1703-5. PubMed ID: 19457553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of gene profiling in chronic myeloid leukaemia.
    Yong AS; Melo JV
    Best Pract Res Clin Haematol; 2009 Jun; 22(2):181-90. PubMed ID: 19698927
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Abnormalities in glucose uptake and metabolism in imatinib-resistant human BCR-ABL-positive cells.
    Kominsky DJ; Klawitter J; Brown JL; Boros LG; Melo JV; Eckhardt SG; Serkova NJ
    Clin Cancer Res; 2009 May; 15(10):3442-50. PubMed ID: 19401345
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Update: chronic myelogenous leukemia clinical practice guidelines.
    O'Brien SM; Kantarjian H; Radich J
    J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S29-40. PubMed ID: 19795574
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.